May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Progressive Subretinal Fibrosis Despite Anti-VEGF Therapy in Exudative Age-Related Macular Degeneration
Author Affiliations & Notes
  • R. Iranmanesh
    Ophthalmology-Columbia Univ, Columbia University, New York, New York
  • L. Del Priore
    Ophthalmology-Columbia Univ, Columbia University, New York, New York
  • S. Chang
    Ophthalmology-Columbia Univ, Columbia University, New York, New York
  • Footnotes
    Commercial Relationships  R. Iranmanesh, None; L. Del Priore, None; S. Chang, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5568. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Iranmanesh, L. Del Priore, S. Chang; Progressive Subretinal Fibrosis Despite Anti-VEGF Therapy in Exudative Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5568. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To describe the progression and/or persistence of subretinalfibrosis despite anti-VEGF therapy in 3 patients with exudativeage-related macular degeneration (AMD).

 
Methods:
 

Case Series

 
Results:
 

The case histories of 3 patients treated with anti-VEGF agentsfor exudative AMD are discussed. Clinical examination, as wellas fluorescein angiography, fundus photography and optical coherencetomography, are shown documenting the progression or persistenceof subretinal fibrosis leading to visual decline despite anti-VEGFtherapy.

 
Conclusions:
 

Anti-VEGF therapy is directed at the angiogenic stimulus forchoroidal neovascularization and leakage; the development ofanti-VEGF therapies has been a significant advance in the managementof exudative AMD. However, subretinal fibrosis can either persistor develop despite the use of such therapy as deposition offibrosis tissue, which is composed principally of collagen andother extra cellular matrix molecules, can be present in exudativeAMD patients despite the use of anti-VEGF therapy. Further progressin the control of subretinal neovascularization may requiredevelopment of agents targeted against other pathways besidesVEGF in the development of exudative AMD.  

 

 
Keywords: age-related macular degeneration • imaging/image analysis: clinical • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×